The decision to halt the rollout of AstraZeneca’s COVID-19 vaccine in Europe is proving to be a major flashpoint. A vanishingly small number of people have developed blood clots after receiving the vaccine and there is currently no causal link to suggest
The decision to halt the rollout of AstraZeneca’s COVID-19 vaccine in Europe is proving to be a major flashpoint. A vanishingly small number of people have developed blood clots after receiving the vaccine and there is currently no causal link to suggest
